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Abstract
Background: Several practice guidelines recommend screening for depression in cancer care, but no systematic reviews
have examined whether there is evidence that depression screening benefits cancer patients. The objective was to evaluate
the potential benefits of depression screening in cancer patients by assessing the (1) accuracy of depression screening tools;
(2) effectiveness of depression treatment; and (3) effect of depression screening, either alone or in the context of
comprehensive depression care, on depression outcomes.
Methods: Data sources were CINAHL, Cochrane, EMBASE, ISI, MEDLINE, PsycINFO and SCOPUS databases through January
24, 2011; manual journal searches; reference lists; citation tracking; trial registry reviews. Articles on cancer patients were
included if they (1) compared a depression screening instrument to a valid criterion for major depressive disorder (MDD); (2)
compared depression treatment with placebo or usual care in a randomized controlled trial (RCT); (3) assessed the effect of
screening on depression outcomes in a RCT.
Results: There were 19 studies of screening accuracy, 1 MDD treatment RCT, but no RCTs that investigated effects of
screening on depression outcomes. Screening accuracy studies generally had small sample sizes (median=17 depression
cases) and used exploratory methods to set sample-specific cutoff scores that varied substantially across studies. A nurse-
delivered intervention for MDD reduced depressive symptoms moderately (effect size=0.37).
Conclusions: The one treatment study reviewed reported modest improvement in depressive symptoms, but no evidence
was found on whether or not depression screening in cancer patients, either alone or in the context of optimal depression
care, improves depression outcomes compared to usual care. Depression screening in cancer should be evaluated in a RCT
in which all patients identified as depressed, either through screening or via physician recognition and referral in a control
group, have access to comprehensive depression care.
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Over 40% of people will be diagnosed with cancer in their
lifetime with two-thirds living at least 5 years [1,2]. Cancer
treatment is often arduous and may include surgery, radiotherapy,
or chemotherapy that can last for months or years. Cancer
patients and survivors often experience decreased quality of life,
reduced capacity to perform daily activities, and mental health
problems. Distress is common, ranging from ‘‘normal’’ distress in
reaction to cancer and its treatment to symptoms that meet criteria
for a psychiatric disorder [3,4]. Prevalence of major depressive
disorder (MDD) is estimated to be approximately 11% among
cancer patients, compared to 5–6% in the general population,
although rates may vary depending on the type of cancer [5,6].
Many cancer patients report that their psychosocial needs are
not addressed adequately, and improving supportive and palliative
care has been prioritized [3,4,7]. A 2002 US National Institutes of
Health (NIH) State-of-the Science Conference Statement [8]
called for the routine use of screening tools to identify untreated
depression among cancer patients. Similarly, among gaps in
psychosocial care, a 2007 report from the Institute of Medicine
(IOM) noted low rates of recognition and treatment for depression
[4]. The IOM report [4] and guidelines from the UK National
Institute for Clinical Excellence (NICE) [7] and the National
Comprehensive Cancer Network (NCCN) [3] recommend
screening for psychological ‘‘distress,’’ including depression, in
cancer patients.
The term screening has been used, sometimes inaccurately, to
describe a number of activities that involve the use of depression
symptom questionnaires, including using the questionnaires to
monitor symptom severity or treatment effects, to detect relapse in
patients who have undergone treatment, to identify patients who
are receiving suboptimal treatment, or to inform the delivery of
psychosocial services that are provided to all patients, regardless of
symptom severity scores. Although these activities are potentially
useful applications of depression symptom questionnaires, none
constitutes screening [9]. Screening, as defined by the UK
National Screening Committee, is ‘‘a public health service in
which members of a defined population, who do not necessarily
perceive they are at risk of, or are already affected by, a disease or
its complications, are asked a question or offered a test to identify
those individuals who are more likely to be helped than harmed by
further tests or treatment to reduce the risk of disease or its
complications’’ (page 6) [10]. Thus, screening for MDD involves
using questionnaires to identify patients who may have depression,
but who are not seeking treatment for symptoms and whose
depression is not otherwise recognized. Patients who screen
positive should be further assessed using a clinical interview to
determine if a diagnosis of MDD is warranted, and, if appropriate,
treated. In addition to evidence from well-designed and conducted
screening randomized controlled trials (RCTs), established criteria
for when recommendations for screening should be considered
[10–12] emphasize the need to assess whether accurate screening
tests with only a tolerably small risk of false positive results are
available and whether there are effective treatments for patients
identified through screening.
No systematic reviews have specifically evaluated the effects of
screening for MDD in cancer patients on depression outcomes.
Thus, the objective of this systematic review was to evaluate
whether evidence supports recommendations for systematic
screening for depression in cancer care. We used the US
Preventive Services Task Force (USPSTF) [13,14] analytic
framework for evaluating evidence for or against screening
programs to develop review questions (see Figure 1). The USPSTF
framework recognizes the need for RCTs to directly assess links
between screening programs and patient outcomes. When direct
evidence from RCTs is not available or is of low quality, the
USPSTF framework assesses key links that are necessary for
Figure 1. USPSTF Framework for Evaluating Screening Programs.
doi:10.1371/journal.pone.0027181.g001
Depression Screening in Cancer
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27181screening to benefit patients, focusing on the need for accurate
screening tools and effective treatments [14]. Thus, we identified
the following key questions for the current review:
Key Question # 1: What is the accuracy of
depression screening instruments among cancer pa-
tients?
Key Question # 2: Does treatment of depression
improve symptoms of depression in cancer patients?
Key Question # 3: Is depression screening of cancer
patients, either alone or in the context of enhanced
depression care, more effective than usual care in
reducing depressive symptoms or diagnoses of MDD?
Methods
Search strategy
The CINAHL, Cochrane, EMBASE, ISI, MEDLINE, Psy-
cINFO and SCOPUS databases were searched through January
24, 2011. One search was conducted to identify articles that
compared a screening instrument with a valid MDD criterion
standard (Key Question #1) or that assessed outcomes from
depression screening, either alone or in the context of enhanced
depression care (Key Question #3). A second search was done for
depression treatment studies (Key Question #2). See Supplemen-
tary Information S1 for search terms. Manual searching was done
on reference lists of included articles, relevant systematic reviews
(Supplementary Information S2), and 45 selected journals (August
2010 to January 2011; Supplementary Information S3). We
tracked citations of included articles using Google Scholar [15],
surveyed authors of included treatment and screening trials, and
searched the trial registries ClinicalTrials.gov [16] and the
International Standard Randomized Controlled Trial Number
Register [17] to attempt to identify unpublished treatment or
screening RCTs.
Identification of eligible studies
Eligible articles included studies in any language on cancer
patients with any type of malignancy at any disease stage that
reported original data, excluding case series or case reports.
Translators assisted reviewers to evaluate titles/abstracts and
articles for languages not covered by investigators, who were able
to independently review material in English, Dutch, French, and
Spanish. Multiple articles on the same cohort were treated as a
single study. Studies with mixed populations were included if
cancer data were reported separately.
Studies on the accuracy of depression screening tools (Key
Question #1) were included if they compared screening results to
a Diagnostic and Statistical Manual of Mental Disorders (DSM) or
International Classification of Diseases (ICD) diagnosis of MDD based
on a validated structured or semi-structured interview (e.g.,
Structured Clinical Interview for DSM-IV [SCID-IV] [18],
Composite International Diagnostic Interview [CIDI] [19],
Diagnostic Interview Schedule [DIS] [20]) administered within 2
weeks of the screening tool and reporting data allowing
determination of sensitivity, specificity, positive predictive value,
and negative predictive value.
Eligible articles on depression treatment (Key Question #2)
were RCTs comparing pharmacological, psychotherapeutic, or
other interventions with placebo or usual care controls among
cancer patients diagnosed with MDD based on a validated
diagnostic interview and DSM or ICD criteria. We required a
valid diagnostic interview because unassisted clinician diagnoses
have poor reliability [21] and because a large proportion of
patients scoring above cutoffs on self-report questionnaires do not
have MDD [22]. Head-to-head trials of different interventions
without a comparison to usual care or placebo were not eligible.
Eligible articles for Key Question #3 were RCTs that
compared depression outcomes between cancer patients who
underwent depression screening and those who did not. We
searched for both screening studies that included the provision of
comprehensive depression care for patients with depression as part
of the screening program and studies that screened patients, but
did not provide such care. Changes in rates of depression
recognition and treatment were noted, but not included as
depression outcomes. This is because increased treatment without
improved depression outcomes would expose patients to costs and
potential harms without benefit. Screening was defined per the
UK National Screening Committee’s definition [10]. Thus,
eligible screening trials had to include a case identification strategy
based on an a priori defined cutoff score on a depression screening
tool to make decisions regarding further assessment or treatment.
Studies in which both intervention and control groups received the
same psychosocial services, but service providers in the interven-
tion group had access to results from psychosocial questionnaires
that may have informed their interactions, but did not necessarily
determine service allocation decisions, were not included. Studies
in which questionnaire results were provided to clinicians without
guidance on cutoff scores to determine positive screening status
were also excluded. Finally, studies that administered multiple
screening tools for multiple problems were not included, since
determining whether depression screening influenced depression
outcomes would not be possible.
Two investigators independently reviewed articles for eligibility.
If either deemed an article potentially eligible based on title/
abstract review, then a full-text review was completed. Disagree-
ments after full-text review were resolved by consensus.
Evaluation of eligible studies
Two investigators independently extracted and entered data
into a standardized spreadsheet (see Supplementary Information
S4). Discrepancies were resolved by consensus. For Key Question
#1 (diagnostic accuracy), the Quality Assessment for Diagnostic
Accuracy Studies tool (QUADAS) [23] was used for quality
assessment (see Supplementary Information S5). Risk of bias in
studies included for Key Question #2 (treatment) and Key
Question #3 (screening) was assessed with the Cochrane Risk of
Bias tool [24] (see Supplementary Information S6). Study quality
and risk of bias were assessed by 2 investigators with discrepancies
resolved by consensus.
Data presentation and synthesis
In studies included for Key Question #1 (diagnostic accuracy),
for each screening instrument, sensitivity, specificity, positive
predictive value, and negative predictive value with 95%
confidence intervals (CIs) [25] were extracted based on primary
cutoffs identified by study authors. For Key Questions #2
(treatment) and #3 (screening), when multiple depression
outcomes were reported, designated primary outcomes for each
study were prioritized, followed by observer-rated scales, then self-
report measures. Post-intervention effect sizes were reported using
the Hedges’s g statistic [26], which represents a standardized
difference between 2 means, as well as r
2, which is statistically
equivalent [27,28], but presents results in terms of percent of
variance in depression change scores due to treatment. Response
and remission were presented as relative risk ratios using study
definitions.
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determine whether there was sufficient clinical and methodological
similarity to support pooling of results. For Key Question #1,
studies were heterogeneous in terms of patient samples, screening
tools and cutoffs, criterion standards, and whether they used a
priori-defined, standard scoring thresholds versus sample-specific
thresholds based on exploratory receiver operating characteristic
(ROC) curve methods. Only 1 eligible study was identified for Key
Question #2 and none for Key Question #3. Thus, results were
not pooled quantitatively.
A review protocol was not published or registered for this study.
However, a protocol was followed for searching, data extraction,
and data synthesis with all methods determined a priori.
Results
Key Question #1: Diagnostic Accuracy of Depression
Screening Tools
The database search for Key Questions #1 (diagnostic
accuracy) and #3 (screening) generated 2,302 unique citations
(Figure 2). For Key Question #1 (diagnostic accuracy), 2,193 were
excluded after title/abstract review and 91 after full-text review.
Two additional eligible articles [29,30] were identified through
alternative sources, resulting in 20 included articles [29–48]. Two
of these articles [37,38] reported on the same cohort, leaving 19
unique studies for review.
The 19 studies reviewed included 8 studies of breast cancer
patients [29,30,33,35,40,41,44,46] and 11 of patients with mixed
cancer sites [31,32,34,36–39,42,43,45,47,48] across the spectrum
of cancer stages (Table 1). Sample sizes in the 19 patient cohorts
ranged from 16 to 381 (median=128), and the number of cases of
MDD from 6 to 74 (median=17). In 12 studies [31–
39,41,44,47,48], diagnostic accuracy data were reported using
an optimal cutoff score that maximized accuracy based on
exploratory ROC methods (Table 2); 1 study [46] used
exploratory methods for the study’s primary screening tool and
compared results to literature-based cutoffs for 2 other screening
tools; 1 study [45] used exploratory methods to identify an optimal
cutoff among a small set of possible cutoffs from the literature; and
5 studies [29,30,40,42,43] reported on standard cutoff scores from
the screening literature.
There were 6 studies [31,32,36–38,44,48] of the Hospital
Anxiety and Depression Scale (HADS). The 6 studies included
between 14 and 30 MDD cases. All used exploratory ROC
methods, and they identified optimal screening cutoffs that ranged
from 15 to 20. Nine studies [31,33,35–38,41,44,47,48] with 14 to
40 MDD cases per study, used ROC methods with the HADS
depression subscale (HADS-D) and reported optimal cutoff scores
Figure 2. PRISMA Flow Diagram of Study Selection Process for Key Question #1.
doi:10.1371/journal.pone.0027181.g002
Depression Screening in Cancer
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27181from 5 to 11. Only 3 studies [30,40,46] used a priori defined
standard cutoffs, 8 [46] or 11 [30,40], to assess diagnostic accuracy
with the HADS-D and reported sensitivities of 7% to 50%. Two
studies [37–39] used ROC methods with the Edinburgh Postnatal
Depression Scale (EPDS) and identified optimal cutoff scores of 12
and 13, similar to the standard cutoff of 13 used in two other
studies [30,43]. Excluding a study with only 6 MDD cases [43],
sensitivity with the EPDS ranged from 72% to 82%, specificity
from 74% to 90%, positive predictive value from 42% to 54%, and
negative predictive value from 86% to 97%. Apart from the
HADS anxiety subscale, no other screening tool was used in more
than one study (see Table 2). One study [29] assessed the yield of
screening with and without excluding patients with psychiatric
disorders already treated with psychotropic medications and found
that the true positive rate of depression screens fell from 21% to
7% after excluding patients who were already receiving treatment
prior to screening.
As shown in Table 3, the methodological quality of the 19
diagnostic accuracy studies was generally adequate for administering
the same reference test to all patients in the study; for the reference
being independent of the screening test; and for adequately
describing the screening and diagnostic tests. However, 17 of 19
studies failed to exclude patients who were already diagnosed or
receiving depression treatment and who would not be newly
identified through screening. In addition, 6 studies were rated ‘no’
or ‘unclear’ for clear sample selection criteria, 10 for timing of the
screening tool and diagnostic interview administration, 11 for blind
interpretation of the diagnostic interview, 19 for description of
handling ofmissing data,and 8 forexplanation of study withdrawals.
Key Question #2: Effect of Depression Treatment
For Key Question #2, 2,923 unique citations were identified.
As shown in Figure 3, 2,870 were excluded after title/abstract
review, and 52 after full-text review, leaving 1 eligible RCT. That
study [49] of patients with MDD based on the SCID-IV
randomized 99 patients to usual cancer care and 101 to usual
care plus a nurse-delivered collaborative care depression inter-
vention (Table 4). The intervention involved up to 10 one-to-one
sessions (mean=7) over 3 months. Sessions included education
about depression and its treatment, problem-solving and coping
strategies, and communication with physicians about depression
management. Study nurses reviewed each patient’s progress with a
psychiatrist weekly and communicated with the patient’s primary
care physician regarding patient progress and psychiatrist
recommendations. Post-intervention depression scores were sig-
nificantly reduced compared to the usual care group (Hedges’s
g=0.37) (see Table 5). Study quality was high (Table 6).
Key Question #3: Effect of Depression Screening
Of 2,302 unique titles/abstracts from the database search, 5
were selected for full-text review, and no RCTs of depression
screening met review eligibility criteria (Figure 4).
Table 1. Patient Characteristics in Studies of Diagnostic Accuracy of Depression Screening Tools.
First Author, Year Country Cancer Site/Description N Mean Age (Years) Males (%)
N (%) Major
Depression
Akechi [31], 2006 Japan Mixed/Terminal 209 61 66 14 (7%)
Alexander [30], 2010 UK Breast/Stage I–IIb (disease-free) 200 58 0 18 (9%)
Coyne [29], 2004 USA Breast/Stage I–IV (Total Sample)
a 113 56 0 10 (9%)
Breast/Stage I–IV (Excluding Treated MDD/GAD)
a 103 56
b 0 3 (3%)
Grassi [32], 2009 Italy Mixed/Local, loco-regional, or metastatic 79 57
c 24
c 14 (18%)
Hopwood [33], 1991 UK Breast/Advanced 81 NR 0 16 (20%)
Houts [34], 2010 USA Mixed/NR 42 55 26 17 (40%)
Krespi Boothby [35], 2010 UK Breast/Early 255 58 0 22 (9%)
Kugaya [36], 1998 Japan Mixed/NR 128 61 63 17 (13%)
Lloyd-Williams [37,38],
2000, 2001
UK Mixed/Life-expectancy ,6 months 100 57 44 22 (22%)
Lloyd-Williams [39], 2007 UK Mixed/Life-expectancy ,6 months 246 62 43 74 (30%)
Love [40], 2002 Australia Breast/Stages I–IIb (excluding T3, N0, M0) 303 NR 0 29 (10%)
Love [41], 2004 Australia Breast/Stage IV 227 52 0 16 (7%)
Meyer [42], 2003 UK Mixed/Terminal 45 NR 42 9 (20%)
Murphy [43], 2006 UK NR/Advanced metastatic cancer in palliative care 16 68 50 6 (38%)
O ¨zalp [44], 2008 Turkey Breast/Mixed 204 51 0 17 (8%)
Passik [45], 2001 USA Mixed/NR 60 58 47 24 (40%)
Patel [46], 2010 Australia Breast/Mixed (excluding Stage IV) 100 53 0 8 (8%)
Smith [47], 2006 UK Mixed/NR 381 56 50 40 (10%)
Walker [48], 2007 UK Mixed/Mixed 361 62 24 30 (8%)
Abbreviations: GAD=General Anxiety Disorder; MDD=Major Depressive Disorder; NR=Not reported; UK=United Kingdom; USA=United States of America.
aStudy reported diagnostic accuracy data for all 113 women in the study, and also after excluding women with MDD already treated with antidepressants and women
with GAD already treated with antidepressants or anxiolytics (N=103).
bMean age based on all 113 women in the study.
cDemographic data are based on full study sample of 109 patients, rather than the 79 patients included in the analyses reported in the table. The authors excluded 30
patients with anxiety or adjustment disorders, but not MDD, from diagnostic accuracy analyses.
doi:10.1371/journal.pone.0027181.t001
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First Author,
Year Country
Major
Depression
Criterion
Standard
Instrument/
Cutoff
Derivation
of Cutoff
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Positive
Predictive
Value %
(95% CI)
Negative
Predictive
Value %
(95% CI)
Akechi [31], 2006 Japan SCID 1 item, ‘‘Depressed?
a NA 79 (52–92) 92 (87–95) 41 (25–59) 98 (95–99)
1 item, ‘‘Lost interest?’’
a NA 93 (68–99) 92 (87–95) 45 (28–62) 99 (97–100)
1 item, ‘‘Depressed’’ or
‘‘Lost Interest?’’
a
NA 100 (78–100) 86 (81–90) 34 (22–49) 100 (98–100)
HADS $17 Exploratory 71 (45–88) 77 (71–83) 19 (10–31) 97 (93–99)
HADS-D $9 Exploratory 86 (60–96) 69 (62–75) 17 (10–27) 99 (95–100)
Alexander [30], 2010 UK SCID EPDS $13 Literature 72 (49–88) 90 (85–94) 42 (26–59) 97 (93–99)
HADS-D $11 Literature 50 (29–71) 97 (94–99) 64 (39–84) 95 (91–97)
Coyne [29], 2004 USA SCID HSCL-25 $44
b Literature 70 (40–89) 75 (66–82) 21 (11–38) 96 (90–99)
HSCL-25 $44
b Literature 67 (21–94) 74 (65–82) 7 (2–23) 99 (93–100)
Grassi [32], 2009 Italy CIDI DT $5 Exploratory 79 (52–92) 83 (72–90) 50 (31–69) 95 (86–98)
HADS $15 Exploratory 86 (60–96) 95 (87–98) 80 (55–93) 97 (89–99)
Hopwood [33], 1991 UK CIS HADS-D $11 Exploratory 75 (51–90) 75 (64–84) 43 (27–61) 92 (82–97)
Houts [34], 2010 USA SCID PCM Acute Distress
Scale $61
Exploratory 100 (82–100) 84 (65–94) 81 (60–92) 100 (85–100)
PCM Despair Scale $63 Exploratory 94 (73–99) 84 (65–94) 80 (58–92) 95 (78–99)
Krespi Boothby [35],
2010
UK SADS HADS-D $7 Exploratory 77 (57–90) 87 (82–91) 36 (24–50) 98 (95–99)
GHQ-12 $4 Exploratory 77 (57–90) 82 (77–86) 29 (19–41) 97 (94–99)
Kugaya [36], 1998 Japan SCID HADS $20 Exploratory 82 (59–94) 96 (91–99) 78 (55–91) 97 (92–99)
HADS-D $11 Exploratory 82 (59–94) 96 (90–98) 74 (51–88) 97 (92–99)
HADS-A $8 Exploratory 94 (73–99) 88 (80–92) 53 (36–70) 99 (94–100)
Lloyd-Williams [37–
38], 2000, 2001
UK PSE HADS $19 Exploratory 68 (47–84) 67 (56–76) 37 (24–52) 88 (77–94)
HADS-D $11 Exploratory 55 (35–73) 74 (64–83) 38 (23–55) 85 (75–92)
HADS-A $10 Exploratory 59 (39–77) 68 (57–77) 34 (21–50) 85 (75–92)
EPDS $13 Exploratory 82 (61–93) 79 (69–87) 53 (37–69) 94 (85–98)
Lloyd-Williams [39],
2007
UK PSE EPDS $12 Exploratory 72 (60–81) 74 (67–80) 54 (44–64) 86 (79–91)
Brief EPDS $6 Exploratory 72 (60–81) 83 (77–88) 65 (54–74) 87 (81–91)
Love [40], 2002 Australia MILP HADS-D $11 Literature 7 (2–22) 98 (95–99) 25 (7–59) 91 (87–94)
Love [41], 2004 Australia MILP HADS-D $7 Exploratory 81 (57–93) 80 (74–85) 24 (14–36) 98 (95–99)
BDI-SF $5 Exploratory 94 (72–99) 63 (56–69) 16 (10–25) 99 (96–100)
Meyer [42], 2003 UK SCID MEQ $90 Literature 56 (27–81) 94 (82–98) 71 (36–92) 89 (76–96)
Murphy [43], 2006 UK SCID EPDS $13 Literature
c 67 (30–90) 100 (72–100) 100 (51–100) 83 (55–95)
O ¨zalp [44], 2008 Turkey SCID HADS $17 Exploratory 71 (47–87) 80 (74–85) 24 (15–38) 97 (93–99)
HADS-D $5 Exploratory 88 (66–97) 59 (52–66) 16 (10–25) 98 (94–100)
HADS-A $7 Exploratory 65 (41–83) 69 (62–75) 16 (9–26) 96 (91–98)
Passik [45], 2001 USA MINI ZSDS $48 Literature/
Exploratory
d
67 (47–82) 86 (71–94) 76 (55–89) 79 (64–89)
BZSDS $22 Literature/
Exploratory
d
96 (80–99) 42 (27–58) 52 (38–66) 94 (72–99)
Patel [46], 2010 Australia CIDI BC-VI $2 Exploratory 88 (53–98) 59 (48–69) 17 (8–30) 98 (90–100)
HADS-D $8 Literature 17 (3–56) 94 (87–98) 20 (4–62) 93 (85–97)
PSYCH-6 $2 Literature 80 (38–96) 68 (56–78) 15 (6–34) 98 (89–100)
Smith [47], 2006 UK SCAN / PSE HADS-D $7 Exploratory 73 (57–84) 64 (59–69) 19 (14–26) 95 (92–97)
HADS-D minus
misfitting items $5
Exploratory 70 (55–82) 60 (55–65) 17 (12–24) 94 (91–97)
Walker [48], 2007 UK SCID HADS $15 Exploratory 87 (70–95) 85 (81–88) 34 (25–45) 99 (96–99)
HADS-D $7 Exploratory 90 (74–97) 88 (84–91) 40 (29–52) 99 (97–100)
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authors or in other reviews as related to screening were excluded
from the present systematic review. Several were excluded because
they did not use a positive depression screen based on a pre-
specified cutoff score to determine which patients would receive
further assessment or treatment. In those studies, a range of
screening tools was often made available for clinical consultations,
but scores on a depression screening tool did not determine
referral for psychosocial evaluation or treatment. Studies were also
excluded because they (1) were not RCTs; (2) included multiple
screening tools for many different problems, not allowing the effect
of depression screening to be evaluated separately; or (3) did not
report depression symptom or diagnosis outcomes.
Discussion
One of the most important functions of systematic reviews is to
identify areas where there is not sufficient evidence and where
clinical trials are needed [50]. The main finding of this systematic
review was that there are no RCTs that have evaluated whether
screening for depression among cancer patients would improve
depression outcomes. This is important because reports from an
NIH panel [8] and the IOM [4] and clinical guidelines from the
NCCN [3] and NICE [7] have recommended that screening for
psychological distress, including depression, be part of standard
supportive and palliative cancer care. The results of this
systematic review show that these recommendation statements
are not supported by evidence from RCTs that screening cancer
patients for depression would improve patients’ mental health
beyond existing psychosocial services that are offered in oncology
settings.
As described in well-established criteria for evaluating the
potential benefit of screening programs [10,12] and methods
developed by the USPSTF [14] in the absence of evidence from
well-conducted RCTs on the benefits versus harms of screening it
is important to examine whether evidence on the performance of
screening tools and the efficacy of treatment is sufficiently robust as
to warrant recommendations for screening and where there are
gaps in the process that require more research.
With respect to the accuracy of depression screening tools in
cancer settings, most studies that we reviewed used exploratory
methods that identify cutoff scores that maximize diagnostic
accuracy in a particular sample. These methods tend to yield
inflated estimates of screening accuracy that do not replicate
consistently in other samples [51]. In addition, sample sizes were
generally small for the purpose of assessing diagnostic accuracy
with a median of 17 MDD cases per study. Not surprisingly,
optimal cutoff scores for the two instruments that were used most
frequently, the HADS and HADS-D, varied too widely to provide
guidance to clinicians on their optimal use. Optimal cutoffs ranged
from 15 to 20 for the HADS and 5 to 11 for the HADS-D. Three
studies that used a priori defined standard cutoffs for the HADS-D
reported very low sensitivity (7% to 50%). The accuracy of the
EPDS was better, with cutoffs of 12 and 13 producing reasonably
high sensitivity (72–82%) and specificity (74–90%) estimates,
although only one study included more than 22 patients with
MDD. All studies for Key Question #1 were based on samples
that included already diagnosed and treated patients. This would
be expected to generate inflated estimates of screening sensitivity
and exaggerate the number of previously undetected cases that
would be identified through screening in clinical practice as
described in a recent overview [52].
With respect to depression treatment, we identified 1 high-
quality RCT of a nurse-delivered collaborative care intervention
for MDD [49]. That study found that cancer patients randomized
to the intervention experienced a small to moderate reduction in
depressive symptoms (Hedges’s g=0.37), similar to the estimated
effect reported in a meta-analysis of collaborative care interven-
tions in primary care (standardized mean effect size=0.25) [53]. A
number of studies have used psychosocial interventions to address
a range of clinical domains associated with cancer, but not MDD,
and were not included in this review [54]. A collaborative care
intervention [55] and several antidepressant trials for depression
[54] were also excluded because they defined MDD based on non-
validated clinician interviews or scores on self-report question-
naires. Results from those studies generally support the conclusion
that depression treatment is similarly effective for patients with and
without cancer [54,55].
The nurse-delivered collaborative care intervention trial
reported by Strong et al. [49] tested the kind of integrated
depression care that might be considered for patients identified as
depressed in a screening program. This trial was included in the
review of treatment effects, but not the effects of screening,
because it only enrolled patients who had been diagnosed with
MDD. Thus, the results of the trial suggest that collaborative care
would improve outcomes for patients already identified as
First Author,
Year Country
Major
Depression
Criterion
Standard
Instrument/
Cutoff
Derivation
of Cutoff
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Positive
Predictive
Value %
(95% CI)
Negative
Predictive
Value %
(95% CI)
HADS-A $9 Exploratory 87 (70–95) 83 (79–87) 32 (23–42) 99 (96–99)
Abbreviations: BC-VI=Breast Cancer - Vulnerability Index; BDI-SF=Beck Depression Inventory Short Form; BZSDS=Brief Zung Self Rating Depression Scale;
CIDI=Composite International Diagnostic Interview; CIS=Clinical Interview Schedule; DT=Distress Thermometer; EPDS=Edinburgh Postnatal Depression Scale;
GHQ=General Health Questionnaire; HADS=Hospital Anxiety and Depression Scale total score; HADS-A=Anxiety subscale of Hospital Anxiety and Depression Scale;
HADS-D=Depression subscale of Hospital Anxiety and Depression Scale; HSCL-25=25-item version of the Hopkins Symptom Checklist; MILP=Monash Interview for
Liaison Psychiatry; MINI=Mini-International Neuropsychiatric Interview; NA=Not applicable; PCM=Patient Care Monitor; PSE=Present State Examination; PSYCH-6=6-
item subscale measuring symptoms of depression and anxiety from the Somatic and Psychological Health Report (SPHERE); SADS: Schedule for Affective Disorders and
Schizophrenia; SCAN=Schedule for Clinical Assessment in Neuropsychiatry; SCID=Structured Clinical Interview for DSM; ZSDS=Zung Self Rating Depression Scale.
aItems were embedded in the diagnostic interview, and at least 1 of 2 was required for a diagnosis of major depression.
bStudy reported diagnostic accuracy data for all 113 women in the study (first line), and also after excluding women with MDD already treated with antidepressants and
women with GAD already treated with antidepressants or anxiolytics (N=103; second line).
cA cutoff of 13 or greater on the EPDS is standard, although the authors did not indicate this explicitly.
dAuthors used several different cutoffs from the literature and tested to determine optimal cutoff in their sample.
doi:10.1371/journal.pone.0027181.t002
Table 2. Cont.
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of whether patients from a cancer setting who are screened would
have better outcomes than patients who are not screened, but who
could receive collaborative depression care after referral by a
healthcare provider outside of the context of screening. Per
standard criteria for evaluating screening programs [10–12],
RCTs of screening assess outcomes for patients screened versus
patients not screened. Thus, an important limitation of our review
was that there were no RCTs that compared depression outcomes
among patients screened for depression compared to patients not
screened for depression.
Depression Screening in Context
Depression screening is only useful to the degree that it leads to
improved outcomes above and beyond existing care. Thus, to be
successful, a screening program would need to identify a
meaningful number of patients as depressed out of those who
have opted not to utilize available psychosocial supports;
successfully enroll those patients in treatment; and achieve
positive treatment results. As illustrated by one study from
Germany [56], however, the desire for psychosocial support to
cope with cancer may not be correlated with distress levels, and
nearly as many patients with low levels of distress may desire
supportive care as patients above the cutoff criterion on a
screening tool. To provide incremental benefit to patients,
depression screening programs in cancer must be able to uncover
and address unmet needs [57].
As described in the recently updated NICE guidelines for
depression care in general medical settings, it should not be
assumed that screening programs would necessarily meet
currently unmet care needs. The NICE guidelines noted a lack
of evidence for benefit from depression screening and, therefore,
Table 3. Quality Assessment of Studies of Diagnostic Accuracy (QUADAS).
QUADAS Items
a
First Author,
Year
#1 Patient
Spectrum
b
#2
Selection
Criteria
Clear
#4
Timing of
Ref and
Index
Tests
c
#5 Whole
Sample
Received
Ref Test
#6A l l
Patients
with
Same
Ref Test
#7 Ref
Indep of
Index Test
#8
Index
Test
Descrip
#9 Ref
Test
Descrip
#11 Ref
Interpret Blind
to Index
#13
Missing
Data
d
#14
Study
With-
drawals
Akechi [31], 2006 No Yes Yes Yes Yes Yes (HADS)
No (single
item)
Yes Yes Unclear (HADS)
No (single item)
Unclear No
Alexander [30], 2010 No Yes Unclear Yes Yes Yes Yes Yes Unclear Unclear Yes
Coyne [29], 2004 Yes Yes Unclear Yes Yes Yes Yes Yes Unclear Unclear Unclear
Grassi [32], 2009 No Yes Yes Yes Yes Yes Yes Yes Yes Unclear No
Hopwood [33], 1991 No Yes Unclear No Yes Yes Yes No Yes Unclear Yes
Houts [34], 2010 No No Yes
e Yes Yes Yes Yes Yes Yes Unclear Yes
Krespi Boothby [35],
2010
No Unclear Yes Yes Yes Yes Yes No Yes Unclear No
Kugaya [36], 1998 No No Yes Yes Yes Yes Yes Yes Yes Unclear No
Lloyd-Williams
[37,38], 2000, 2001
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Unclear Yes
Lloyd-Williams [39],
2007
No Yes Unclear Yes Yes Yes Yes Yes Yes Unclear Yes
Love [40], 2002, No Yes Unclear Yes Yes Yes Yes Yes Unclear Unclear Unclear
Love [41], 2004 No Yes Unclear Yes Yes Yes Yes Yes Unclear Unclear Unclear
Meyer [42], 2003 No Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes
Murphy [43], 2006 No Unclear Yes Yes Yes Yes Yes Yes Unclear Unclear Yes
O ¨zalp [44], 2008 No Yes Yes Yes Yes Yes Yes Yes Yes Unclear Yes
Passik [45], 2001 No No Unclear Yes Yes Yes Yes Yes No Unclear Yes
Patel [46], 2010 No Yes No
f Yes Yes Yes Unclear Yes Unclear Unclear Yes
Smith [47], 2006 No No Yes Unclear Yes Yes Yes Yes Unclear Unclear Unclear
Walker [48], 2007 No Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes
aSee Supplementary Information S5 for QUADAS items. Items are rated ‘yes’, ‘no’ and ‘unclear’ based on the user’s guide
23 and reflecting the likelihood of being free of
bias. Items #3 (reference standard appropriate), #10 (blind interpretation of test results) and #12 (same clinical data available as in practice) were not evaluated
because an appropriate reference standard was a criterion for review eligibility and because scoring of all self-report depression screening tools is fully automated and
does not require judgment.
bItem #1 scored ‘no’ if patients with already diagnosed or treated depression were not excluded from study sample as they would not constitute newly identified cases
in clinical practice. Studies were not downgraded for only sampling one type or stage of cancer.
cItem #4 scored ‘yes’ if index test and reference standard were administered within 1 week of each other, ‘no’ if longer, and ‘unclear’ if not specified. Studies in which a
significant number of patients received assessments more than 2 weeks apart were not included in the systematic review.
dItem #13 originally was ‘‘Were uninterpretable, indeterminate or intermediate test results reported?’’ This item was adapted as ‘‘Were missing data on the index test
handled correctly?’’.
eAuthors clarified that most patients received the index test and reference standard on the same day and all within 5 days.
fAuthors clarified that 67% of interviews were conducted within one week and 93% within 2 weeks.
doi:10.1371/journal.pone.0027181.t003
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strategies to identify depression among high-risk groups of
patients or patients otherwise identified by physicians as possibly
having depression [58]. In addition to the overall lack of evidence
for benefits from screening, the authors of the NICE report cited
a number of other important considerations, including the
relatively small proportion of patients who screen positive on
screening tools who actually have depression. They noted that
many patients who screen positive are mildly depressed and are
likely to recover without formal intervention, and that ineffective
screening could divert scarce resources from more seriously
depressed patients who may receive inadequate treatment as a
result [58,59].
Based on existing evidence from other patient groups, it is clear
that screening without comprehensive systems for depression
assessment and management does not improve depression
outcomes. There are at least 11 trials in primary care [60], for
instance, that have tested whether screening and referral for
depression treatment improves depression outcomes, and all have
been negative. Some of these primary care trials have found that
screening increases the number of patients treated for depression,
but increasing treatment without symptom reduction would be
costly and could expose patients to unnecessary harms from
treatment without benefit [60]. Thus, the USPSTF recommends
depression screening in primary care only when supported by
integrated, staff-assisted depression management programs [61].
However, it is not clear whether screening in the context of staff-
assisted, collaborative care depression management programs
would benefit patients [62], and it is important to differentiate
between the effectiveness of screening and the effectiveness of
collaborative care. The results of the collaborative care treatment
trials reviewed by the USPSTF suggest that providing collabo-
rative depression care is better than not providing this care. They
do not, however, demonstrate that patients who receive screening
will have better depression outcomes compared to patients who
are not screened when the same treatment and care resources are
made available to both groups [9]. This is because, as in the
Strong et al. study [49], in the studies reviewed by the USPSTF,
Figure 3. PRISMA Flow Diagram of Study Selection Process for Key Question #2.
doi:10.1371/journal.pone.0027181.g003
Table 4. Characteristics of Randomized Controlled Trial of Depression Treatment.
First Author,Year
Study Funding
Source
Cancer Site/
Description Treatment vs. Control
Number of Patients
Randomized
Mean Age
(Years) Males (%)
Strong [49], 2008 Non-Industry Mixed/Mixed Nurse Intervention vs. UC Total: 200; Tx: 101; UC: 99 Total: 57; Tx: 57;
UC: 57
Total: 30%; Tx:
31%; UC: 28%
Abbreviations: Tx=treatment; UC=usual care.
doi:10.1371/journal.pone.0027181.t004
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diagnosis of depression to be eligible for the trial. In addition,
only patients with depression in the intervention groups received
a collaborative care intervention for depression, whereas
depressed patients in the control groups received only standard
care. In actual clinical settings, patients receive the optimal
treatment available, whether they are identified through a
screening program or via physician recognition. Thus, these
trials do not address the issue of whether screening would benefit
patients with previously unrecognized depression. Underlining
this issue, in the largest of the trials cited by the USPSTF a
substantial portion of patients were already recognized and being
treated for depression prior to enrolling in the trial and receiving
augmented care [9].
Potential Harms from Depression Screening in Cancer Care
In the absence of demonstrated benefit, potential harms from
depression screening for cancer patients should be considered
carefully, as outlined in standard evaluative frameworks [10–12]
and in the USPSTF methodology [14]. The degree to which
routine depression screening of patients with cancer might lead to
inappropriate labeling and treatment on the one hand, or to
extraordinary and impractical overuse of important health care
resources, on the other, has not been examined. Routine
depression screening would increase the number of cancer patients
diagnosed with depression and treated with antidepressant drugs
[29,63]. As a consequence, more patients with cancer would be
exposed to potentially harmful drug-drug interactions between
antidepressants and either cancer chemotherapeutic agents [63–
67] or anti-emetics [68]. Interactions between anti-cancer drugs
and antidepressants are of particular concern because small
alterations in the plasma concentrations of certain members of
either drug class can lead to either subtherapeutic effects or drug
toxicity [64]. Perhaps of greatest importance is the potential
interaction between certain antidepressants and tamoxifen,
commonly used as adjuvant therapy for women with breast
cancer. The hepatic enzyme CYP2D6 is the principal enzyme that
converts tamoxifen to its active metabolite, endoxifen [67]. Some
antidepressants, particularly paroxetine, fluoxetine, and bupropi-
on, are strong inhibitors of CYP2D6 and may diminish the
therapeutic effect of tamoxifen [29,65,66]. Indeed, one study
estimated that there would be 1 additional breast cancer death
within 5 years of stopping adjuvant treatment for every 20 women
who used paroxetine approximately 40% of the time they took
tamoxifen [63].
Conclusions
In summary, this systematic review did not identify any RCTs
that compared the benefits versus harms of depression screening
in patients with cancer. In the absence of such RCTs, there
currently is not evidence to support recommendations for the
incorporation of routine depression screening into standard
Table 5. Results of Randomized Controlled Trial of Depression Treatment.
First Author,Year
Number (%) Lost
to Follow-up
Treatment
Duration Depression Outcomes
a
Remission:
b N( % )
and Relative Risk
Ratio (95% CI)
Response:
c N( % )
and Relative Risk
Ratio (95% CI)
Primary Outcome:
Hedges’s g
(95% CI) and r
2
Secondary
Outcome(s):
Hedges’s g
(95% CI) and r
2
Strong [49], 2008 Total: 4 (2%); Tx:
0 (0%); UC: 4 (4%)
Mean of 7 sessions
over 3 months
(a) Tx
d 28 (28%); UC:
14 (14%); RR=2.0
(1.1 to 3.5); (b) Tx
e 65
(64%); UC: 44 (44%);
RR=1.4 (1.1 to 1.9)
(a) Tx
d 51 (50%);
UC: 34 (34%);
RR=1.5 (1.1 to 2.1)
SCL-20 depression
f
g=0.37 (0.09 to
0.65); r
2=0.03
NR
Abbreviations: CI=confidence interval; NR=not reported; RR=relative risk ratio; SCL-20 depression=depression subscale derived from the Symptom Checklist-90;
Tx=treatment; UC=usual care.
aDepression outcomes were assessed at the end of the treatment period. Continuous outcomes that favored the treatment group are reported in this table as positive
numbers.
bRemission defined as (a) ,0.75 on the SCL-20 and (b) no longer having major depression based on the SCID-IV.
cResponse defined as a 50% reduction in SCL-20 score from baseline.
dPublication included remission and response data for 97 patients in the intervention group and 99 in the usual care group. In this table, patients lost to follow-up are
counted as non-remitters and non-responders.
ePublication included remission data for 96 patients in the intervention group and 98 in the usual care group. In this table, patients lost to follow-up are counted as non-
remitters.
fUnadjusted effect size g calculated from mean SCL-20 scores 3 months post-randomization for 97 patients randomized to the intervention group and 99 randomized to
the usual care group, as shown in Table 2 of Strong et al.
50
doi:10.1371/journal.pone.0027181.t005
Table 6. Assessment of Risk of Bias in Randomized Controlled Trial in Key Question #2 (Treatment).
Cochrane Risk of Bias Tool Items
a
First Author,
Year
#1 Sequence
Generation
#2 Allocation
Concealment #3 Blinding
#4 Incomplete
Outcome Data
#5 Selective
Outcome Reporting
#6 Other
Sources of Bias
#7 Overall Risk
of Bias Rating
Strong [49], 2008 low low uncertain low low low low
aSee Supplementary Information S6 for item descriptions. Items are scored as ‘high’, ‘low’, or ‘uncertain’ risk of bias.
doi:10.1371/journal.pone.0027181.t006
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cancer care as in other settings, but important limitations in the
evidence base on screening tools in this population were
identified, and research is needed to address these limitations.
In order to inform health care providers who must decide
whether or not to screen cancer patients for depression and
developers of guidelines for cancer care, well-designed and
executed RCTs that investigate depression screening programs
are needed. Specifically, screening for depression in a cancer
treatment setting should be tested in a trial where all patients
identified as depressed via screening or by physician recognition
and referral in a control group have access to high-quality,
integrated depression care. Given the current absence of evidence
on the effectiveness of screening in cancer, and the absence of
positive results from any trial in other patient groups, however,
recommendations for depression screening among patients with
cancer are at this point premature.
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